A Phase 3 interventional study of Imlunestrant and Exemestane in Breast Neoplasms and Neoplasm Metastasis, sponsored by Eli Lilly and Company. Active, not recruiting at 243 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 6th largest by enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 in phase 3, reaches primary completion later than 10 of the 21 other live ones, and was the 77th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, France and 4 more countries
Ages 18+ · Women only
Eli Lilly and Company · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, China, Germany and 2 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 47 · Phase 3 16 · Phase 4 4
First in 1998; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 874 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 138 across the 80 interventional studies. Of the 61 that completed or were terminated, 40 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Breast Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05514054Phase 3Eli Lilly and CompanyA Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have disease that has demonstrated progression on or after an aromatase inhibitor alone or in combination with a cyclin-dependent kinase (CDK)4/6 inhibitor
-- Participants are expected to have received prior treatment with a CDK4/6 inhibitor, if this treatment is approved and can be reimbursed
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Imlunestrant 400 milligrams (mg) orally once daily on days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation were met.
Drug: Imlunestrant
Participants received the investigator's choice of endocrine therapy, either exemestane 25 mg administered orally once daily on days 1 to 28 of a 28-day cycle, or Fulvestrant 500 mg intramuscularly on days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond, until disease progression or a criterion for discontinuation was met.
Drug: Exemestane · Drug: Fulvestrant
Participants received Imlunestrant 400 mg orally once daily on Days 1 to 28 of a 28-day cycle, plus Abemaciclib 150 mg orally twice daily on Days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation was met.
Drug: Imlunestrant · Drug: Abemaciclib
Administered orally.
Also known as: LY3484356
Administered orally.
Administered IM.
Administered orally.
Also known as: LY2835219
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)
PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
Investigator-assessed PFS (Between Arm C and Arm A)
PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)
Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B)
PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
Blinded Independent Review Committee (BIRC) Assessed PFS (Between Arm A and Arm B)
PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
Blinded Independent Review Committee (BIRC) Assessed PFS (Between Arm C and Arm A)
PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 25 months)
Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm A and Arm B)
ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.
Time frame: Randomization until measured progressive disease (up to 28 months)
Investigator-assessed Duration of Response (DoR) (Between Arm A and Arm B)
DoR is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
Time frame: From Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up To 26 Months)
Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm A and Arm B)
CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Randomization until measured progressive disease (up to 28 months)
Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm C and Arm A)
ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.
Time frame: Randomization until measured progressive disease (up to 26 months)
Investigator-assessed Duration of Response (DoR) (Between Arm C and Arm A)
DoR is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
Time frame: From Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up To 19 Months)
Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm C and Arm A)
CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Randomization until measured progressive disease (up to 26 months)
Time to Sustained Worsening of the "Worst Pain" as Measured by Worst Pain NRS (Between Arm A and Arm B)
Time to sustained worsening of worst pain is defined as the time from randomization to the first increase (≥2 points) in the weekly average of the worst pain score, with confirmation in the next consecutive week. It was measured by the Worst Pain Numeric Rating Scale (NRS). NRS is a single-item, participant-administered, 11-point horizontal scale ranging from 0 to 10, with 0 representing "no pain" and 10 representing "pain as bad as you can imagine." Participants not known to have sustained worsening will be censored at the last documented assessment.
Time frame: Randomization through follow-up (up to 24 months)
Time to Sustained Worsening of the "Worst Pain" as Measured by Worst Pain NRS (Between Arm C and Arm A)
Time to sustained worsening of worst pain is defined as the time from randomization to the first increase (≥2 points) in the weekly average of the worst pain score, with confirmation in the next consecutive week. It was measured by the Worst Pain Numeric Rating Scale (NRS). NRS is a single-item, participant-administered, 11-point horizontal scale ranging from 0 to 10, with 0 representing "no pain" and 10 representing "pain as bad as you can imagine." Participants not known to have sustained worsening will be censored at the last documented assessment.
Time frame: Randomization through follow-up (up to 20 months)
Pharmacokinetics (PK): Plasma Concentration of Imlunestrant
* Sampling timepoints for PK outcome analysis were relative to Imlunestrant dosing. * For Cycle 1 Day 1, sampling occurred at a "single" timepoint within the 2- to 4-hour window after Imlunestrant dosing, with the timepoint varying across analyzed participants.
Time frame: Cycle 1 Day 1 (within 2 to 4 hours post-dose), Cycle 2 Day 1 (Predose), Cycle 3 Day 1 (3 hours post-dose, 5 hours post-dose), Cycle 4 Day 1 (Predose)
Pharmacokinetics (PK): Plasma Concentration of Total Abemaciclib
* Plasma concentration of total abemaciclib is the concentration of the parent abemaciclib and its metabolites in the plasma. * Sampling timepoints for PK outcome analysis were relative to Imlunestrant dosing. * For Cycle 1 Day 1, sampling occurred at a "single" timepoint within the 2- to 4-hour window after Imlunestrant dosing, with the timepoint varying across analyzed participants.
Time frame: Cycle 1 Day 1 (within 2 to 4 hours post-dose), Cycle 2 Day 1 (Predose), Cycle 3 Day 1 (3 hours post-dose, 5 hours post-dose), Cycle 4 Day 1 (Predose)
Overall Survival (OS) in the ITT Population
OS in the ITT population
Time frame: Randomization until death from any cause (estimated as up to 5 years)
OS in the ESR1-mutation Detected Population
OS in the ESR1-mutation detected population
Time frame: Randomization until death from any cause (estimated as up to 5 years)
Blinded Independent Review Committee (BIRC) Assessed PFS in the ESR1-Mutation Detected Population (Between Arm A and Arm B)
PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)
ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.
Time frame: Randomization until measured progressive disease (up to 28 months)
Investigator-assessed Duration of Response (DoR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)
DoR is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
Time frame: From Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up To 24 Months)
Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B)
CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Randomization until measured progressive disease (up to 28 months)
The study was initially planned with participants randomized 1:1 to either arm A or arm B. Following a protocol amendment, arm C was added later, after randomization to arms A and B had already begun.
| Milestone | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy | Arm C: Imlunestrant + Abemaciclib |
|---|---|---|---|
| Started | 331 | 330 | 213 |
| Analysis population for the comparison between arm a and arm b | 331 | 330 | 0 |
| Analysis population for the comparison between arm c and arm a | 213 | 0 | 213 |
| Estrogen receptor 1 (esr1) mutation-detected population for comparison between arm a and arm b | 138 | 118 | 0 |
| Received at least 1 dose of study drug | 326 | 324 | 209 |
| Safety analysis population | 327 | 324 | 208 |
| Completed | 246 | 264 | 117 |
| Not completed | 85 | 66 | 96 |
| Withdrew: Withdrawal by subject | 6 | 16 | 6 |
| Withdrew: Physician decision | 0 | 3 | 1 |
| Withdrew: Adverse event | 10 | 1 | 12 |
| Withdrew: On study treatment (ongoing) | 65 | 43 | 75 |
| Withdrew: Protocol deviation | 4 | 3 | 2 |
PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
| Months | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy |
|---|---|---|
| Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) | 5.55 (5.32 to 7.26) | 5.52 (4.60 to 5.62) |
PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
| Months | Arm C: Imlunestrant + Abemaciclib | Arm A: Imlunestrant |
|---|---|---|
| Investigator-assessed PFS (Between Arm C and Arm A) | 9.36 (7.49 to 11.86) | 5.49 (3.78 to 5.62) |
PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
| Months | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy |
|---|---|---|
| Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) | 5.49 (3.91 to 7.39) | 3.84 (3.68 to 5.52) |
PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
| Months | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy |
|---|---|---|
| Blinded Independent Review Committee (BIRC) Assessed PFS (Between Arm A and Arm B) | 9.23 (7.33 to 11.07) | 7.36 (5.55 to 9.40) |
PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
| Months | Arm C: Imlunestrant + Abemaciclib | Arm A: Imlunestrant |
|---|---|---|
| Blinded Independent Review Committee (BIRC) Assessed PFS (Between Arm C and Arm A) | 14.52 (11.37 to NA) | 9.23 (5.49 to 13.70) |
ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.
| Percentage of participants | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy |
|---|---|---|
| Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm A and Arm B) | 10.3 (7 to 13.5) | 6.4 (3.7 to 9) |
DoR is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
| Months | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy |
|---|---|---|
| Investigator-assessed Duration of Response (DoR) (Between Arm A and Arm B) | 11.10 (7.43 to 23.92) | 7.39 (5.59 to 15.67) |
CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| Percentage of participants | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy |
|---|---|---|
| Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm A and Arm B) | 46.8 (41.5 to 52.2) | 45.5 (40.1 to 50.8) |
ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.
| Percentage of participants | Arm C: Imlunestrant + Abemaciclib | Arm A: Imlunestrant |
|---|---|---|
| Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm C and Arm A) | 21.1 (15.6 to 26.6) | 9.4 (5.5 to 13.3) |
DoR is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
| Months | Arm C: Imlunestrant + Abemaciclib | Arm A: Imlunestrant |
|---|---|---|
| Investigator-assessed Duration of Response (DoR) (Between Arm C and Arm A) | 11.07 (9.13 to NA) | 10.02 (6.57 to 15.01) |
CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| Percentage of participants | Arm C: Imlunestrant + Abemaciclib | Arm A: Imlunestrant |
|---|---|---|
| Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm C and Arm A) | 62.9 (56.4 to 69.4) | 44.1 (37.5 to 50.8) |
Time to sustained worsening of worst pain is defined as the time from randomization to the first increase (≥2 points) in the weekly average of the worst pain score, with confirmation in the next consecutive week. It was measured by the Worst Pain Numeric Rating Scale (NRS). NRS is a single-item, participant-administered, 11-point horizontal scale ranging from 0 to 10, with 0 representing "no pain" and 10 representing "pain as bad as you can imagine." Participants not known to have sustained worsening will be censored at the last documented assessment.
| Months | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy |
|---|---|---|
| Time to Sustained Worsening of the "Worst Pain" as Measured by Worst Pain NRS (Between Arm A and Arm B) | NA (NA to NA) | NA (NA to NA) |
Time to sustained worsening of worst pain is defined as the time from randomization to the first increase (≥2 points) in the weekly average of the worst pain score, with confirmation in the next consecutive week. It was measured by the Worst Pain Numeric Rating Scale (NRS). NRS is a single-item, participant-administered, 11-point horizontal scale ranging from 0 to 10, with 0 representing "no pain" and 10 representing "pain as bad as you can imagine." Participants not known to have sustained worsening will be censored at the last documented assessment.
| Months | Arm C: Imlunestrant + Abemaciclib | Arm A: Imlunestrant |
|---|---|---|
| Time to Sustained Worsening of the "Worst Pain" as Measured by Worst Pain NRS (Between Arm C and Arm A) | NA (NA to NA) | NA (NA to NA) |
* Sampling timepoints for PK outcome analysis were relative to Imlunestrant dosing. * For Cycle 1 Day 1, sampling occurred at a "single" timepoint within the 2- to 4-hour window after Imlunestrant dosing, with the timepoint varying across analyzed participants.
| nanograms per milliliter | Arm A: Imlunestrant | Arm C: Imlunestrant + Abemaciclib |
|---|---|---|
| Cycle 1 Day 1 (within 2 to 4 hours postdose) | 45.7 ± 123 | 56.5 ± 122 |
| Cycle 2 Day 1 (Predose) | 76 ± 76 | 64.9 ± 103 |
| Cycle 3 Day 1 (3 hours post-dose) | 141 ± 70 | 144 ± 73 |
| Cycle 3 Day 1 (5 hours post-dose) | 136 ± 69 | 146 ± 69 |
| Cycle 4 Day 1 (Predose) | 85.2 ± 69 | 63 ± 97 |
* Plasma concentration of total abemaciclib is the concentration of the parent abemaciclib and its metabolites in the plasma. * Sampling timepoints for PK outcome analysis were relative to Imlunestrant dosing. * For Cycle 1 Day 1, sampling occurred at a "single" timepoint within the 2- to 4-hour window after Imlunestrant dosing, with the timepoint varying across analyzed participants.
| nanograms per milliliter | Arm C: Imlunestrant + Abemaciclib |
|---|---|
| Cycle 1 Day 1 (within 2 to 4 hours postdose) | 158 ± 120 |
| Cycle 2 Day 1 (Predose) | 792 ± 82 |
| Cycle 3 Day 1 (3 hours post-dose) | 880 ± 74 |
| Cycle 3 Day 1 (5 hours post-dose) | 926 ± 64 |
| Cycle 4 Day 1 (Predose) | 783 ± 59 |
OS in the ITT population
Results for this outcome have not been posted.
OS in the ESR1-mutation detected population
Results for this outcome have not been posted.
PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
| Months | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy |
|---|---|---|
| Blinded Independent Review Committee (BIRC) Assessed PFS in the ESR1-Mutation Detected Population (Between Arm A and Arm B) | 7.43 (4.83 to 11.07) | 5.49 (3.84 to 6.70) |
ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.
| Percentage of participants | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy |
|---|---|---|
| Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B) | 11.6 (6.3 to 16.9) | 5.9 (1.7 to 10.2) |
DoR is defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).
| Months | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy |
|---|---|---|
| Investigator-assessed Duration of Response (DoR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B) | 10.02 (3.98 to 14.59) | 5.59 (2.92 to 7.79) |
CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| Percentage of participants | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy |
|---|---|---|
| Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) in the ESR1-Mutation Detected Population (Between Arm A and Arm B) | 46.4 (38.1 to 54.7) | 36.4 (27.8 to 45.1) |
Collected over Baseline up to 28 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Imlunestrant | 62/327 (19%) | 46/327 (14.1%) | 250/327 (76.5%) |
| Arm B: Investigator's Choice of Endocrine Therapy - Exemestane | 8/32 (25%) | 6/32 (18.8%) | 26/32 (81.3%) |
| Arm B: Investigator's Choice of Endocrine Therapy - Fulvestrant | 82/292 (28.1%) | 49/292 (16.8%) | 229/292 (78.4%) |
| Arm C: Imlunestrant + Abemaciclib | 36/208 (17.3%) | 42/208 (20.2%) | 203/208 (97.6%) |
| Event | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy - Exemestane | Arm B: Investigator's Choice of Endocrine Therapy - Fulvestrant | Arm C: Imlunestrant + Abemaciclib |
|---|---|---|---|---|
| Cardiac arrestCardiac disorders | 1/327 | 1/32 | 2/292 | 0/208 |
| General physical health deteriorationGeneral disorders | 0/327 | 1/32 | 1/292 | 0/208 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/327 | 1/32 | 0/292 | 0/208 |
| Tibia fractureInjury, poisoning and procedural complications | 0/327 | 1/32 | 0/292 | 0/208 |
| Cerebellar infarctionNervous system disorders | 0/327 | 1/32 | 0/292 | 0/208 |
| Neuropathy peripheralNervous system disorders | 0/327 | 1/32 | 0/292 | 0/208 |
| Peripheral artery thrombosisVascular disorders | 0/327 | 1/32 | 0/292 | 0/208 |
| PneumoniaInfections and infestations | 2/327 | 0/32 | 3/292 | 4/208 |
| DiarrhoeaGastrointestinal disorders | 1/327 | 0/32 | 0/292 | 3/208 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 4/327 | 0/32 | 0/292 | 0/208 |
| Event | Arm A: Imlunestrant | Arm B: Investigator's Choice of Endocrine Therapy - Exemestane | Arm B: Investigator's Choice of Endocrine Therapy - Fulvestrant | Arm C: Imlunestrant + Abemaciclib |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 71/327 | 3/32 | 37/292 | 180/208 |
| NauseaGastrointestinal disorders | 59/327 | 4/32 | 39/292 | 104/208 |
| AnaemiaBlood and lymphatic system disorders | 38/327 | 8/32 | 45/292 | 91/208 |
| VomitingGastrointestinal disorders | 31/327 | 1/32 | 15/292 | 66/208 |
| NeutropeniaBlood and lymphatic system disorders | 10/327 | 0/32 | 5/292 | 55/208 |
| Neutrophil count decreasedInvestigations | 10/327 | 0/32 | 15/292 | 47/208 |
| FatigueGeneral disorders | 45/327 | 2/32 | 19/292 | 46/208 |
| Blood creatinine increasedInvestigations | 11/327 | 1/32 | 7/292 | 44/208 |
| Aspartate aminotransferase increasedInvestigations | 47/327 | 3/32 | 46/292 | 43/208 |
| Decreased appetiteMetabolism and nutrition disorders | 26/327 | 1/32 | 14/292 | 42/208 |
All randomized participants.
| Age, Continuous(years) | Imlunestrant | Investigator's Choice of Endocrine Therapy | Imlunestrant + Abemaciclib | Total |
|---|---|---|---|---|
| Mean | 60.4 ± 11.6 | 60.8 ± 12.0 | 61.9 ± 11.1 | 60.9 ± 11.6 |
| Sex: Female, Male(Participants) | Imlunestrant | Investigator's Choice of Endocrine Therapy | Imlunestrant + Abemaciclib | Total |
|---|---|---|---|---|
| Female | 327 | 329 | 211 | 867 |
| Male | 4 | 1 | 2 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Imlunestrant | Investigator's Choice of Endocrine Therapy | Imlunestrant + Abemaciclib | Total |
|---|---|---|---|---|
| Hispanic or Latino | 79 | 80 | 37 | 196 |
| Not Hispanic or Latino | 218 | 216 | 148 | 582 |
| Unknown or Not Reported | 34 | 34 | 28 | 96 |
| Race (NIH/OMB)(Participants) | Imlunestrant | Investigator's Choice of Endocrine Therapy | Imlunestrant + Abemaciclib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 23 | 16 | 3 | 42 |
| Asian | 92 | 96 | 72 | 260 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 11 | 7 | 8 | 26 |
| White | 186 | 191 | 111 | 488 |
| More than one race | 2 | 7 | 3 | 12 |
| Unknown or Not Reported | 17 | 13 | 16 | 46 |
| Estrogen Receptor 1 (ESR1)-Mutation(Participants) | Imlunestrant | Investigator's Choice of Endocrine Therapy | Imlunestrant + Abemaciclib | Total |
|---|---|---|---|---|
| Detected | 138 | 118 | 67 | 323 |
| Not detected | 193 | 212 | 146 | 551 |
Showing the first 100 of 243 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2021 to primary completion in Jun 2024, 32 months.
Results were first posted in Jul 2025, 1 year after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 32 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imlunestrant